Latest news with #DiabetesCare
News18
6 days ago
- Health
- News18
The Japanese 15-Minute After-Meal Stroll: A Simple Habit Backed By Science
Last Updated: A simple 15-minute stroll after meals, inspired by Japanese wellness, can boost digestion, regulate blood sugar, and aid weight loss naturally. In Japan, health isn't just a lifestyle, it's a cultural habit rooted in simplicity and mindfulness. One such practice gaining global attention is the 15-minute post-meal walk, a gentle stroll taken shortly after eating. Known in Japanese wellness culture as shoku-go sanpo (食後散歩), this easy ritual has been quietly contributing to improved digestion, blood sugar regulation, and weight management for centuries. Why Walk After a Meal? Unlike intense workouts or diet fads, the after-meal walk is surprisingly gentle—yet remarkably effective. Research shows that walking for just 10 to 15 minutes after meals can help reduce blood sugar spikes, support digestion, and prevent fat accumulation. 'When you take a short walk after eating, your muscles help absorb glucose from the bloodstream, lowering blood sugar levels naturally," says Dr. Meera Jaisinghani, an internal medicine specialist based in Mumbai. 'It also aids digestion by stimulating gastric motility and helps reduce bloating. Over time, this small habit can make a big difference in weight control and metabolic health." The Science Behind the Stroll A study published in Diabetes Care (2022) found that intermittent post-meal walking even for just 2 to 5 minutes significantly reduced glucose levels compared to prolonged sitting. The 15-minute window seems to be especially beneficial after heavier meals, helping to avoid insulin spikes that can lead to fat storage and cravings. Walking also promotes the 'afterburn effect," or excess post-exercise oxygen consumption (EPOC), which helps burn a few extra calories even after the walk ends. And unlike workouts that require gym wear and motivation, a light walk is sustainable even in your work clothes. A Lifestyle, Not a Trend In Japanese cities, it's common to see elderly couples and young professionals alike taking slow-paced walks after dinner. It's not just about weight loss, it's about longevity, mental clarity, and consistency. The meditative rhythm of walking can also help reduce stress hormones like cortisol, which are known to contribute to abdominal fat. How to Start: Aim for a relaxed 10–15-minute walk 15–30 minutes after your meal. Walk at a conversational pace. Avoid stairs or intense cardio, this is about movement, not strain. The Japanese post-meal stroll isn't a fitness craze, it's a time-tested habit. Add it to your daily routine and watch how this one simple act gently reshapes your relationship with food, fitness, and your body. view comments First Published: July 24, 2025, 18:33 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Gizmodo
18-07-2025
- Health
- Gizmodo
This Simple Strategy Could Curb One of Semaglutide's Worst Side Effects
Semaglutide's ability to help people lose weight is legendary, but so are the side effects. The active ingredient in medications Wegovy and Ozempic, semaglutide is renowned for causing severe nausea in some people, sometimes to the extent that they stop treatment. But new research published in the journal Diabetes Care suggests there may be a simple way to combat that effect. Led by a team in Israel, the researchers found that giving people more time and flexibility to ramp up to the recommended 1 milligram dose of the drug seemed correlated with lower levels of nausea. People who followed the slower dosing schedule also seemed less likely to stop using the drug than those who followed a more typical regimen. What's more, the slow-and-steady group still lost about as much weight as their peers. Semaglutide works by mimicking GLP-1, a hormone that plays a key role in regulating our metabolism and hunger. Since U.S. regulators first approved the drug in 2017 to treat diabetes, it has become highly sought after for its appetite-stifling effects and weight-loss benefits—but it has its trade-offs. At least a third of people taking GLP-1s report feeling nauseous, while others also experience constipation and gastrointestinal distress. How Ozempic Works—and What's Still a Mystery As people increase their dose of the drug, the unpleasant GI effects can get worse before they get better. Typically, they fade over time once people reach their recommended dose, but at least some never make it that far and just stop taking the medication. In the new trial, researchers split 104 people with type 2 diabetes into two groups: One set took increasing amounts of semaglutide on a typical, 8-week dosing program, while the other group ramped up their dose on a slower, more flexible schedule that took 16 weeks. People in the second group were also told to hold off on upping their dose if they experienced any GI symptoms and wait till they felt better. Both groups were tracked for 24 weeks. Overall, both groups saw similar improvements to their weight and blood sugar control. But flexible users were less likely to report having nausea than their peers (45.1% vs 64.2%), and experienced fewer days of nausea (2.88 vs 6.3 days per month). Perhaps most notably, only 2% of flexible patients stopped taking the drug by the study's end, compared to 19% of standard users. 'Slower, flexible titration improved adherence and reduced adverse events without compromising efficacy,' the study authors wrote. 'Extremely Severe' Obesity in American Kids Is Surging, Study Finds While some doctors have anecdotally reported similarly positive experiences in their patients who switched to a slower schedule, the study's results are limited: The sample size is quite small, for one, and more work in larger and more diverse groups will be needed to understand if different dosing schedules could help more people stay on their medication, without getting the pukes.
Globe and Mail
10-07-2025
- Business
- Globe and Mail
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?
Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest glucose sensor. The latest development is expected to bolster the company's Diabetes Care business. ABT Stock's Likely Trend Following the News Following the announcement, Abbott's shares moved down slightly 0.2%, finishing at $133.36 on Tuesday. On a positive note, Abbott's Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users. Hence, we expect the market sentiment toward ABT stock to turn positive surrounding the latest approval. Abbott has a market capitalization of $231.78 billion. The company's earnings yield of 3.9% surpasses the industry's 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters. Significance of ABT's FreeStyle Libre 3 Plus Earlier, people living with diabetes had to monitor their glucose levels by pricking their finger to draw blood and then test it with a glucose meter. It can be painful and inconvenient. Approximately 12 million Canadians are living with diabetes, with around 90% or more having type 2 diabetes. Glucose monitoring is crucial to effective diabetes management, as it enables individuals with diabetes to understand how their body responds to food, exercise and medication. Abbott has revolutionized diabetes care with its world-leading FreeStyle Libre continuous glucose monitoring portfolio. The latest FreeStyle Libre 3 Plus makes glucose monitoring simpler and more user-friendly. It measures glucose levels in interstitial fluid through a small sensor worn on the back of the upper arm. The sensor sends glucose data to an accompanying smartphone app, allowing users to track their glucose levels in real-time and manage diabetes more effectively. There is full or partial reimbursement for Libre systems in more than 40 countries. Industry Prospects Favor Abbott Per a Grand View Research report, the global CGM devices market size is projected to reach $7.51 billion by 2030, at a CAGR of 7.19% from 2024 to 2030. The market growth is propelled by the rising prevalence of diabetes due to aging, obesity, and unhealthy lifestyle and increasing demand for the treatment and preventive measures across the globe. Other Recent Developments by Abbott In May, the FDA approved Abbott's Tendyne transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This life-changing therapy is available for patients whose mitral valves are not functioning properly due to severe mitral annular calcification. Additionally, in April, the company launched a next-generation delivery system for its neuromodulation business, designed to simplify electrode implantation for the Proclaim DRG neurostimulation system. ABT Stock Price Performance Over the past year, Abbott's shares have risen 29.3%, surpassing the industry 's 11.6% growth. ABT's Zacks Rank and Other Key Picks Abbott currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Align Technology ALGN, Boston Scientific BSX and Cencora COR. Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry's 9.9% rise. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry's 3.3% decline in the past year. ALGN carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Boston Scientific, currently carrying a Zacks Rank #2, has an earnings yield of 2.8% compared with the industry's 0.6%. Shares of the company have surged 129.7% compared with the industry's 35.9% growth. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 25.9% against the industry's 14.4% decline. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report
San Francisco Chronicle
05-07-2025
- Health
- San Francisco Chronicle
Asian and Pacific Islander teens face higher prediabetes risk, study finds
Asian and Pacific Islander adolescents who are overweight or obese are twice as likely to have prediabetes compared to their white counterparts, according to new research from Kaiser Permanente. Twenty-seven percent of Asian youths had prediabetes compared to 12% of white youths, according to the study, which was published this week in Diabetes Care. All youths in the study were overweight or obese. And there were significant differences in prediabetes rates among Asian subgroups: Native Hawaiian or Pacific Islander youth were at highest risk (32%), followed by South Asian (31%), Filipino (28%), Chinese (26%) and Vietnamese (18%), the study found. The analysis is one of the first to break down prediabetes rates in Asian subgroups rather than grouping all Asians together as a single monolith, which many medical research studies typically do. The findings are important because they reinforce that some people are more likely to develop prediabetes — a condition where one's blood sugar level is higher than normal, but not high enough to be considered diabetes — than their peers, and should perhaps get tested more frequently or earlier to prevent it. 'We need to think about certain populations as being at higher risk, and maybe they need to be screened for prediabetes at a lower threshold,' said study co-author Dr. Louise Greenspan, a pediatric endocrinologist at Kaiser Permanente San Francisco Medical Center. 'We lump all adolescents into one category, and we'd love to be able to personalize things a little more.' Screenings also give doctors a chance to educate patients and their families about diabetes and talk to them about lifestyle factors that can help their health, she said. There is no standard recommendation for when adolescents should start getting screened for diabetes. The U.S. Preventive Services Task Force, the group of medical experts that issues recommendations for what age people should start getting screened for breast cancer and other diseases, does not have a recommendation on diabetes screenings for youths. The American Diabetes Association recommends screening for high-risk ethnic groups who are overweight. Kaiser screens all adolescents who are overweight, regardless of race or ethnicity. It's not clear why Asian youths are more likely than white youths to develop prediabetes, or why some subgroups of Asian youths are more prone than other subgroups. Some potential explanations could be differences in genetics, cultural factors and social determinants of health like income level and neighborhood — or a combination of all those things. 'We know genetics contribute to the risk of developing prediabetes and type 2 diabetes, but the environment that someone grows up in can push them over the edge,' Greenspan said. 'If they're living in a neighborhood where they don't have access to safe places to exercise, or their school doesn't have adequate physical education, or they live in a food desert … those all lead to less activity and more food intake than someone who lives in an environment where it's safe to ride their bike to meet friends in the park and come home to meals parents are able to resource that are plant-based.' The study included about 38,000 Kaiser Permanente Northern California members between ages 10 and 17 who were overweight (85th to 95th percentile BMI for their age) or obese (96th percentile or higher BMI for their age) at a pediatric visit between 2012 and 2019, and had a hemoglobin A1c test within a year of that visit. A1c measures one's average blood sugar level over the last three months. An A1c level between 5.7% and 6.4% is considered prediabetic. The findings add to an already established body of research showing that Asian adults are at a higher risk of developing type 2 diabetes at a lower BMI than white adults. It's not entirely clear why, but some researchers have posited it may be because Asians tend to store more fat around abdominal organs, known as visceral fat, which may lead to heightened insulin resistance. This led to the American Diabetes Association in 2015 recommending that Asian adults get screened for diabetes at a BMI of 23 rather than a BMI of 25, which is the standard screening threshold for all adults.
Yahoo
04-07-2025
- Business
- Yahoo
Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best NASDAQ growth stocks to buy for the next 3 years. On June 24, Corcept Therapeutics announced positive results from the CATALYST trial of Korlym (mifepristone). The data was presented at the American Diabetes Association's 85th Scientific Sessions and also published in Diabetes Care. It showed that Korlym improved glucose control in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes. The trial met its primary endpoint, as patients receiving Korlym experienced a 1.47% decrease in HbA1c from baseline, as compared to a 0.15% decrease in the placebo group. Those on a 900mg dose saw a 2.01% HbA1c improvement. Beyond blood sugar, Korlym also led to reductions in body weight (by 5.1 kg) and waist circumference (by 5.1 cm), even as patients reduced or stopped other glucose-lowering medications. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. The CATALYST trial is the largest to date investigating hypercortisolism in difficult-to-control type 2 diabetes. Its initial phase screened 1,057 patients and found that 24% had hypercortisolism, which made them eligible for the treatment phase. Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
